What happened in optometry this week: July 29 - August 2
Catch up on what happened in optometry during the week of July 29-August 2.
Catch up with what Optometry Times shared this week:
Eyenovia and SGN Nanopharma team up to develop a treatment for chronic DED
By Jordana Joy, Associate Editor
Eyenovia and SGN Nanopharma have announced a collaboration agreement with the end goal to develop a treatment for chronic dry eye disease.1 The ophthalmic and nano-pharmaceutical companies are working to develop SGN’s micellar nanoparticle platform (MNP), a platform-based cyclosporine formulation to be used with Eyenovia’s Optejet dispenser, according to a news release.
Sinus congestion can lead to vision changes, dry eye syndrome
By Shawna L. Vanderhoof, OD, FAAO
Your first patient of the day’s chief complaint is “I have pain behind my eye,” “I have a headache over my eye,” “My vision is fluctuating,” “My eyes are itchy and red,” or all of the above. Where do you start?
The first 2 complaints always take the most time to figure out exactly what is happening and why there is pain because symptoms can range from mildly bothersome to very severe very quickly. Is it an acute or chronic issue? Constant or intermittent?
Zeiss study finds that parents are concerned regarding screen time’s impact on children’s eye health
By Jordana Joy, Associate Editor
For the start of Children’s Eye Health and Safety Month, Zeiss Vision Care has released results from a survey that garnered data regarding concerns, behaviors, and spending habits to parents’ maintaining and protecting their children’s long-term eye health.1 The survey was conducted on a nationwide scale, with its 1000 participants being parents with children aged 18 and under, according to a news release.
Nicox announces recruitment of last US patient in Denali Phase 3 trial of NCX 470
By David Hutton, Managing Editor, Ophthalmology Times
Nicox SA announced the recruitment and randomization of the last patient in the US in its Denali Phase 3 trial of NCX 470.
The company noted that NCX 470 is a novel NO-donating bimatoprost eye drop currently in Phase 3 clinical development.
According to a news release, the Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension and topline results continue to be expected in H2 2025, based on this completion of recruitment of patients in the U.S. and continuing good progress of the trial in China, where recruitment of patients is still ongoing. More than 95% of the total target number of patients have been randomized in this trial so far.
How to identify treatment failure and initiate medication switches
By Mark E. Schaeffer, OD, FAAO
As optometrists, we frequently deal with the complex diagnosis of glaucoma. Although most patients have some awareness of glaucoma, many confuse it with other conditions and often misunderstand the intricacy and seriousness of the disease.
Once diagnosed with any form of glaucoma (eg, primary open angle, angle closure, or any of the secondary types), patients will have to manage this condition for a lifetime. This is why we must focus on educating patients on the need for regular comprehensive eye examinations and highlighting the importance of maintaining treatment during every checkup. As eye care specialists responsible for the health of the ocular surface, we have to establish the need for treatment and provide the necessary assistance to ensure proper disease management.
